about
Guidance for Efficient Small Animal Imaging Quality ControlAmyloid PET and MRI in Alzheimer's disease and mild cognitive impairment.Multimodality rodent imaging chambers for use under barrier conditions with gas anesthesia.A new fast and fully automated software based algorithm for extracting respiratory signal from raw PET data and its comparison to other methods.Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodentsDevelopment and performance test of an online blood sampling system for determination of the arterial input function in rats.Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography.32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113.Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrierInteraction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomographyDose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance proteinSynthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoateA novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.Kinetic modeling in pre-clinical positron emission tomography.[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice.On the applicability of [18F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy.Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[18F]fluoro-β-d-allofuranosyl)-2-nitroimidazole (β-6'-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia.Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease.Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP.[(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.Design, Synthesis, and Evaluation of a Low-Molecular-Weight (11)C-Labeled Tetrazine for Pretargeted PET Imaging Applying Bioorthogonal in Vivo Click Chemistry.Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.Radiosynthesis of [124I]iodometomidate and biological evaluation using small-animal PET.Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography.Preclinical in vitro &in vivo evaluation of [(11)C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1.Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018.Development of a (18) F-labeled tetrazine with favorable pharmacokinetics for bioorthogonal PET imaging.
P50
Q30275741-BB12ADEB-341E-4052-B8E0-910AF5ED1C8FQ33466415-93001F3D-59DD-4404-BA45-FC1F60484693Q33605798-4EEA96E9-3F25-4DCE-85CF-15CFF8DBBE9CQ33751254-C14650C1-013B-428E-916E-EAB579BB9DA6Q34100185-204F4FC4-77B7-484A-9F22-BF01DBD77DA0Q35148312-E520F2E1-F94A-4D5C-B406-E28A80164F1BQ35985746-A9C13171-E688-4145-9021-2BB3E58995B1Q36049576-ACB4E42A-8B80-41AC-9DD7-B26D2B4B6213Q36386154-00F7556B-292B-4559-AD6B-ED4B2F08E05BQ36462753-0C783C14-89BF-4D0A-A6CD-A4F4DEAD6BFCQ36809104-755DC8CB-3601-44D1-AF81-8CFF25BABFC7Q36935382-28C3E88E-83B8-4142-946D-2F1C6A6BE4DBQ36949082-6E62A396-CD9C-400A-B3B7-0BF7B8ABE82AQ36949086-5DF2E84E-217C-4961-90F7-C235D5600037Q36949089-037E1A3B-08A0-4861-88CA-38FA2960D0BFQ36949407-31C1F64E-F68A-47E7-BC2D-CA712005D88FQ36949815-25E93BC0-78E6-438B-8DA7-A08A94A366E5Q36949854-D288AE3D-5170-474F-B1BF-0222E4C7DF46Q36949859-C392DB32-8C34-4244-AD70-33AD04590573Q36949864-F54E739F-9681-479F-8FBE-828419E62873Q36955931-601530D8-B9A2-4229-8241-7A84F5D9EC57Q37177013-0A8F1B76-8312-4F2B-B1FC-57FDEEA0FC63Q37185659-8A33311C-2246-4096-805D-5BC82DB85BFDQ38195959-B9A1DC1C-FC23-4186-B369-705F72C7FA58Q38701499-6DBCD681-5A13-4B78-A114-36FB76A1B1C8Q38731582-127EC1E4-19F7-4C0E-AA62-6E2AC252FD5CQ38747004-40F6C885-BA25-4F1E-AC10-FC214B933DDCQ39213026-EB73083C-5A47-46AA-9EC1-3CBF91C5A373Q39516398-7140D4B4-76EB-4448-81E5-737AA5940B67Q39873732-91ABCB39-771F-45EB-AA1D-4F382D953F5FQ40017032-44D6D606-69A4-4FA6-98B9-20E57FD4CC47Q40213366-66CAFAC5-C116-4397-828D-F7187A958FE5Q41139974-D7C515EC-26C0-43F2-829C-274866C8B383Q47296127-D8BD4C29-A09E-4840-845D-06ED5CD82567Q47845084-4729ED10-6675-4A49-B2B9-C6B9BE2DA873Q47956682-07024405-DD60-4A92-8CBC-DCC26BB29E02Q48087258-54E7AF60-F5D6-4D8E-9759-DB9457EE4066Q48453239-1E36A22E-B6F0-4BB2-BB4E-5B385E35243EQ48513004-7E54B45E-D19C-4840-9453-D38F52EA6B77Q48681676-E80CE346-D92D-4177-AEF7-7D7075E157B0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudia Kuntner
@ast
Claudia Kuntner
@en
Claudia Kuntner
@es
Claudia Kuntner
@nl
Claudia Kuntner
@sl
type
label
Claudia Kuntner
@ast
Claudia Kuntner
@en
Claudia Kuntner
@es
Claudia Kuntner
@nl
Claudia Kuntner
@sl
prefLabel
Claudia Kuntner
@ast
Claudia Kuntner
@en
Claudia Kuntner
@es
Claudia Kuntner
@nl
Claudia Kuntner
@sl
P1053
F-6049-2014
P106
P1153
55894169700
P21
P2798
P31
P3829
P3835
claudia-kuntner
P496
0000-0002-5988-1434